Supernus Pharmaceuticals
SUPN
237 hedge funds and large institutions have $1.57B invested in Supernus Pharmaceuticals in 2023 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 85 increasing their positions, 93 reducing their positions, and 31 closing their positions.
1,075% more call options, than puts
Call options by funds: $611K | Put options by funds: $52K
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0.77% less ownership
Funds ownership: 105.13% → 104.37% (-0.77%)
9% less repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 93
4% less funds holding
Funds holding: 248 → 237 (-11)
9% less capital invested
Capital invested by funds: $1.72B → $1.57B (-$151M)
29% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 31
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$8.73M |
| 2 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
+$7.53M |
| 3 |
BlackRock
New York
|
+$6.68M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$4.57M |
| 5 |
CAM
Congress Asset Management
Boston,
Massachusetts
|
+$4.48M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Pacer Advisors
Malvern,
Pennsylvania
|
-$13.7M |
| 2 |
Two Sigma Investments
New York
|
-$5.79M |
| 3 |
Dimensional Fund Advisors
Austin,
Texas
|
-$3.54M |
| 4 |
BC
Burney Company
Reston,
Virginia
|
-$3.49M |
| 5 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
-$2.95M |
SUPN Hedge Fund Activity: Q3 2023 in Review
237 of the 6,310 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q3 2023, worth a combined $1.57B — down 8.8% from $1.72B a quarter earlier.
Sellers outnumbered buyers: 31 funds closed out of SUPN and 22 opened new positions — a net loss of 9 holders — while 93 trimmed existing stakes and 85 added.
The largest buyer was Citadel Advisors, adding an estimated $8.73M. The largest seller was Pacer Advisors, cutting an estimated $13.7M.
- 237 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q3 2023, down from 248 in Q2 2023.
- Funds reported $1.57B of Supernus Pharmaceuticals stock for Q3 2023, down 8.8% quarter-over-quarter.
- 22 funds opened new Supernus Pharmaceuticals positions in Q3 2023 and 31 closed out, a net change of -9 holders.
- The largest Supernus Pharmaceuticals buyer in Q3 2023 was Citadel Advisors, an estimated $8.73M added.
- The largest Supernus Pharmaceuticals seller in Q3 2023 was Pacer Advisors, an estimated $13.7M sold.
Based on aggregated 13F filings for Q3 2023.